- Advanced search
- Immuno Portal
- Malaria Portal
heparin is an approved drug (FDA (1939))
Compound class: Metabolite or derivative
Comment: Heparin is an endogenous secretory glycosaminoglycan (GAG) that is released predominantly from connective tissue mast cells. Isolated heparin is used clinically as an anti-coagulant. Structurally, heparins (generally known as unfractionated heparin) are a heterogeneous group of anionic, sulfated GAGs. Commercial preparations usually vary in size from 12-15 kDa, while a low molecular weight (fractionated) versions are also available. Database entries may specify the sodium salt forms.
SARS-CoV-2: There is strong experimental evidence which shows that heparin interacts directly with GAG-binding motifs on the Spike glycoprotein of SARS-CoV-2 , and that inhibiting this interaction can reduce SARS-CoV-2 infection of host cells [6,8]. These findings suggest that heparin may offer repurposing potential as a prophylactic COVID-19 therapeutic , in addition to its benefit as a treatment for COVID-19-related thrombotic complications.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Compound class||Metabolite or derivative|
|Approved drug?||Yes (FDA (1939))|
|WHO Essential Medicine||WHO Essential Medicines List (EML) (22nd List, 2021). Access PDF version.
Click to view more information about the WHO Model Lists of Essential Medicines.
|International Nonproprietary Names|
|Reactome Reaction||R-HSA-140791, R-HSA-140806, R-HSA-140870, R-HSA-140872|
|CAS Registry No.||9005-49-6|
|GtoPdb PubChem SID||178101031|
|Search Google for chemical match using the InChIKey||ZFGMDIBRIDKWMY-PASTXAENSA-N|
|Search Google for chemicals with the same backbone||ZFGMDIBRIDKWMY|
|Search PubMed clinical trials||heparin sodium|
|Search PubMed titles||heparin sodium|
|Search PubMed titles/abstracts||heparin sodium|
|UniChem Compound Search for chemical match using the InChIKey||ZFGMDIBRIDKWMY-PASTXAENSA-N|
|UniChem Connectivity Search for chemical match using the InChIKey||ZFGMDIBRIDKWMY-PASTXAENSA-N|